| Business Summary | | Dyax
Corp.
is
a
biopharmaceutical
company
that
has
developed
and
patented
a
method
known
as
phage
display.
The
method
is
used
to
identify
a
range
of
compounds
with
potential
for
the
treatment
and
diagnosis
of
diseases.
The
Company
is
also
using
this
method
to
identify
compounds
that
can
be
used
in
purifying
and
manufacturing
biopharmaceuticals
and
chemicals.
In
addition,
Dyax
develops,
manufactures
and
sells
chromatography
separation
systems
and
consumables
through
its
Biotage
subsidiary.
Its
customers
use
the
Company's
systems
and
consumables
in
separation
processes
from
the
discovery
scale,
where
small
amounts
of
a
compound
are
purified
for
research
work,
through
the
preparative
and
production
scales,
where
a
product
is
manufactured
for
commercialization.
The
Company
is
also
a
developer
and
manufacturer
of
chromatography
systems
that
use
disposable
cartridges
to
purify
pharmaceuticals
being
produced
for
research
and
clinical
development. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Dyax
Corp.
is
a
biopharmaceutical
company
that
has
developed
and
patented
a
method,
known
as
phage
display,
used
to
identify
a
range
of
compounds
with
potential
for
the
treatment
and
diagnosis
of
diseases.
For
the
six
months
ended
6/30/01,
total
revenues
rose
49%
to
$15.3
million.
Net
loss
fell
17%
to
$7.2
million.
Results
reflect
increased
revenues
from
research
collaborations
and
licensing
arrangements,
partially
offset
by
increased
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Henry Blair, 57 Chairman,
Pres, CEO | $475K | $26K | Gregory Phelps, 52 Vice
Chairman | 327K | 34K | Stephen Galliker, 54 Exec.
VP- Fin. and Admin., CFO | -- | -- | Scott Chappel, Ph.D., 50 Exec.
VP of Research and Technology | -- | -- | David Patteson, 45 Exec.
VP, Separations Division and Pres of Biotage, Inc. | 269K | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|